An Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of ABX464 in HIV-1 Seronegative and Seropositive Adults

Trial Profile

An Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of ABX464 in HIV-1 Seronegative and Seropositive Adults

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Oct 2017

At a glance

  • Drugs ABX 464 (Primary)
  • Indications HIV infections
  • Focus Pharmacokinetics
  • Sponsors Abivax
  • Most Recent Events

    • 04 Oct 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Oct 2017.
    • 18 Sep 2017 According to an Abivax media release, the first patient has been dosed in the second cohort, initial results of the first cohort are expected in the first week of October and results from cohort are expected in the second quarter of 2018.
    • 17 Mar 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top